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Abstract
We examined the influence of desired and undesired effects of pharmacological treatment 
on quality of life among relatively stable patients suffering of a psychotic illness. In a cross-
sectional study the effects of antipsychotic medication were measured by Subjects’ 
Response to Antipsychotics Questionnaire (SRA) while Quality of life (QoL) was evaluated 
WHOQoL-BREF. A total of 320 patients agreed to participate in the study. Overall, the 
desired treatment effects predicted an increase in quality of life, while undesired effects 
treatment effects, in particular sedation, affective flattening, and extrapyramidal symptoms 
predicted a decrease. 
Desired effects had less impact on QoL than the undesired effects. The SRA Questionnaire 
appeared to be an acceptable and reliable way to elucidate positive as well as negative 
effects of antipsychotic treatment. The latter have a greater impact on QoL. Further 
research may focus on evaluate its predictive power of treatment adherence in acute as 
well as chronic patients. 
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Introduction 
The primary goal of pharmacological treatment in schizophrenia is the control of psychotic 
symptoms. The price to be paid of the antipsychotic treatment may be undesired effects or 
side effects). There is a growing interest from the consumer or patient perspective in the 
balance between desired and undesired treatment effects, in terms of his/her subjective 
response to medication (Wolters et al., 2006; Hellewel, 2002; Karow and Naber, 2002; 
Voruganti and Awad, 2004). The evaluation by the patient or the subjective reaction to 
antipsychotics has been associated with important clinical factors, such as medication 
adherence (Van Putten et al., 1981; Weiden et al., 1989; Naber et ., 1994; Agarwal et al., 
1998; Garcia Cabeza et al., 2000) , therapeutic effect (Van Putten and May, 1978; Hogan et 
al., 1985; Hogan and Awad, 1992), side-effects (Hogan and Awad, 1992; Van Putten, 1974), 
suicidal behavior (Voruganti and Awad, 2004), and quality of life (QoL) (Naber, 1998). An 
additional aim of antipsychotic treatment is improving the quality of life. In general, 
individuals with severe mental disorders are less satisfied with their life compared to the 
general population (Ritsner et al., 2000). Further effects of antipsychotics like akathisia or 
blunted affect, are strongly associated with a decrease in quality of life. On the other hand, 
reduction of psychotic symptoms is likely to have a positive influence on quality of life. In 
order to improve clinical guidance, it is important to understand the whole range of effects 
that patients experience while treated with antipsychotics. 
The present study will evaluate to what extent patients experience desired as well as 
undesired, positive as well as negative effects of treatment with antipsychotic medication 
and how these relate to quality of life. 
Method 
In a cross-sectional study among in- and outpatients from eight mental health services in 
the Netherlands we included patients with diagnosis in the schizophrenia spectrum 
(schizophrenia or schizo-affective disorder according to DSM-IV criteria) and who were 
treated with classical or atypical antipsychotic medication for at least 6 weeks. Patients 
using lithium or antidepressant medication were exclused. The effects of the antipsychotic 
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medication were measured by the Subjects’ Response to Antipsychotics Questionnaire (SRA) 
(Wolters et al., 2006), a validated and reliable 74-items self-report instrument with eight 
subscales. Subscales of the SRA are: Recovery (24 items), Weight Gain (4 items), Sexual 
Anhedonia (3 items), Sedation (6 items), Affective Flattening (3 items), Extrapyramidal 
Symptoms (5 items), Diminished Sociability (6 items), Increased Sleep (3 items). The desired 
effects or positive response are covered by the 24 Recovery items and the undesired effects 
of negative response by the other subscales, which together form the total negative effect 
scale. Mean scores were calculated by dividing the sum of each scale by the number of 
items. Eighteen miscellaneous items not belonging to a scale were not taken into account 
for this study. Items are scored on a 3-point scale from (1) no, (2) yes to a certain degree, (3) 
yes to a high degree. SRA-Questionnaire has good internal consistency, reproducibility and 
external validity (Wolters et al., 2006). 
Quality of life was measured by the WHOQoL-BREF (The WHOQoL group, 1998), a 26 items 
self-report questionnaire with a 5-point Likert scale ranging from (1) not at all/very poor to 
(5) an extreme amount/very good. Mean scores were calculated according to the 
instructions of the author and ranges from 4 to 20.The WHOQoL-BREF defines QoL as the 
individuals' perceptions of their position in life in the context of the culture and value 
systems in which they live and in relation to their goals, expectations, standards and 
concerns. This definition reflects the view that quality of life refers to a subjective 
evaluation, embedded in a cultural, social and environmental context. The WHOQoL-BREF 
has been developed to provide a short form quality of life assessment with four domain 
level profiles: Physical health (7 items), Psychological health (6 items), Social relationships (3 
items) and Environmental conditions (8 items). Research indicate that the WHOQOL-BREF 
has good to excellent psychometric properties (Skevington et al., 2004). 
Statistics 
The subscales of the SRA and WHOQoL-BREF were analyzed according to the instruction of 
the developers. Descriptive summary statistics for the total sample were calculated for 
sociodemographic characteristics, SRA and WHOQoL-BREF ratings. First the relationship 
between patient characteristics, type of antipsychotic medication, subjects’ response and 
QoL were studied by the means of correlational analysis. Next multiple regression analyses 
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(enter method) was applied with the SRA as independent variable and WHOQoL-BREF as the 
dependent variable. In the first analysis the desirable and total undesirable response were 
included. In the second analysis the subjects’ response was analyzed in more detail with the 
subscales of the SRA. 
Results 
A total of 320 patients - two hundred and thirty four men and eighty six women - agreed to 
participate in the study. Their mean age was 35 years (SD=11.5); 25.5% of the patients used 
classical antipsychotic medication while 23.5% used risperidone 22.5 % clozapine, 19.0% 
olanzapine and 9.5 % quetiapine. Seventeen patients (5.3%) had two different antipsychotic 
medications. Other co-medication (mainly benzodiazepines, N=72) was taken by 126 
patients. Three quarters of the patients (76%) used their medication for more than one 
year.
All patients reported undesired effects (see table 1). The most frequently reported ones 
were Increased Sleep and Weight Gain, while Extrapyramidal Symptoms and Diminished 
Sociability were least reported. All patients also reported, at least to some extent, desired 
effects. There were some significant but rather weak correlations between 
sociodemographic variables and the scores on the subscales of the SRA. Older patients 
reported less Weight Gain (r= -.21), Increased Sleep (r=-.23) and Recovery (r=.-.16). Patients 
with a partner reported more Sexual Anhedonia (r=.11), Sedation (r=.12) and Increased 
Sleep (r=.21). The scores on the WHOQoL-Bref were fairly high, on average above the 
midpoint of the scale. Patients rated highest on the environmental domain of the WHOQoL. 
On the psychological health and social relationship domains their ratings were relatively 
low. There were no significant correlations between sociodemographic variables and the 
scores on the WHOQoL-BREF, except for a weak correlation between gender and the social 
relationships domain: women were more satisfied (r=.16). There were some significant but 
weak correlations between medication characteristics and the WHOQoL-BREF: patients on 
depot medication were less satisfied with their physical health (r= -.13) and patients with 
medication use longer than 1 year were more satisfied with their psychological health 
(r=.16). Type of antipsychotic medication (classical versus atypical) was not significantly 
associated with QoL.
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Table 1. Subjects’ Response to Antipsychotics (SRA) and Quality of Life (WHO QoL 
BREF); mean scores (SD) 
SRA a Mean score (SD) 
Desired response (Recovery) 1.74 (0.46) 
Undesired response (sumscore) 1.51 (0.31) 
Subscales undesired response: 
Weight Gain 1.75 (0.65) 
Sexual Anhedonia 1.46 (0.59) 
Sedation 1.65 (0.49) 
Affective Flattening 1.55 (0.56) 
Extrapyramidal Symptoms 1.40 (0.42) 
Diminished Sociability 1.41 (0.43) 
Increased Sleep 1.77 (0.65) 
WHOQoL-BREFb 
Total score 13.8 (2.8) 
Subscales: 
Physical health 13.9 (2.6) 
Psychological health 13.1 (2.7) 
Social relationships 13.2 (3.2) 
Environment 14.4 (2.6) 
a Range of the scores was 1 (No) to 3 (Yes, in a strong degree); mean score is sum divided by number of items of each scale 
b Range of possible scores was 4 to 20 
The desired response subscale (Recovery) appeared to be associated with higher QoL on all 
domains (see table 2). The sum score of the undesired responses of the SRA showed the 
much higher (negative) correlations with QoL. Most subscales of undesired responses were 
significantly (negatively) associated with the different quality of life domains and with the 
total score. Sedation and Diminished Sociability predicted most strongly of all a lowered 
QoL. Interestingly, Weight Gain and Increased Sleep, although frequently reported 
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The data were further analyzed with multiple regression analysis, summarized in Table 3. All 
correlations were corrected for gender, age, duration of antipsychotic medication use and 
administration mode (oral vs depot). The (total) undesired treatment effects had a higher 
(negative) partial correlation with total QoL and its various domains than the desired effects 
(positive), in particular on the Physical and Psychological health domains. The desired 
effects of recovery were somewhat stronger associated with the Psychological health 
domain. A more detailed analysis of the subscales of the SRA demonstrated that Recovery 
predicted quality of life (total as well as domain scores) better than each of negative effect 
subscales with a few exceptions of the Affective Flattening as to Physical and Psychological 
health. All the subscales of the SRA explained 31% of the variance of the total score QoL, 
most on the physical and psychological domain (both 25% explained variance). 
Discussion 
The present study is an exploratory, cross-sectional survey in a convenience sample of 320 
relatively stable in- and outpatients with a diagnosis in the schizophrenia spectrum receiving 
antipsychotic medications in naturalistic treatment settings, focused on the relation 
between desired and undesired effects of antipsychotic medication and quality of life, as 
experienced by the patients themselves. These effects were recorded by a newly developed 
self-report questionnaire with good psychometric properties and therefore helpful for 
clinicians to be better informed about the prescribed medication. 
A limitation of this study is the selection of patients. Most patients were relatively stable 
outpatients who were willing to be treated with antipsychotics and to participate in a study. 
By not including non-compliers we may have produced an underestimation of the undesired 
treatment effects. Also, by hardly including patients who recently started treatment with 
antipsychotic medication may have caused an underestimation of desired as well as 
undesired treatment effects. So the final selection of patients in our sample may limit the 
generalisability of the results. 
The most frequently reported effect of antipsychotic medication were increased sleep, 
weight gain and recovery. Latter effect is a positive evaluation which may partly be due to 
67
Quality of Life in Schizophrenia in Relation to Patients' Response to Antipsychotics
the composition of this sample of relatively stable patients. Least reported were 
ExtraPyramidal Symptoms (EPS) and social anhedonia. The relative low frequency of EPS 
may be due to the relative low doses of mainly second generation antipsychotics. The 
relative high scores on quality of life may reflect the stable course of the illness, its 
acceptance and adjustment of expectations. Sociodemographic characteristics appear to be 
hardly related to QoL, a finding also reported in healthy people (Myers et al., 1996).
Both desired and undesired effects of the medication have independent effects on the 
subjective quality of life, but the latter effects were nearly twice as large as the former. 
Most patients were not acutely ill and used medication for more than one year, possibly 
contributing to the relative strong correlation of undesired (side) effects with quality of life. 
Nevertheless, the relationship between the desired effect (Recovery) and QoL is substantial 
and not explained by the negative effects. An interpretation of this finding may be that this 
study reflects the situation of patients during a maintenance phase of treatment with 
antipsychotics in which undesired effects attributed to antipsychotic treatment will be 
continously experienced without much improvement. The situation of many patients is such 
that they are tempted to discontinue medication in order to stop or reduce the undesired 
effects and to improve quality of life on the short run. While on the other hand medication 
non-compliance increases the risk of relapse.
Recovery had a high (positive) correlation with quality of life, in particular with the 
psychological and environmental dimension. Sedation, Affective Flattening and 
Extrapyramidal Symptoms predicted a lower Qol. Sedation and Affective Flattening refer to 
the same kind of experiences as negative symptoms and depression, which means that 
these findings are in line with other studies on these symptoms and quality of life (Karow 
and Naber, 2002; Hofer et al., 2004). Extrapyramidal Symptoms predict total score QoL and 
are mainly associated with the environmental domain (Hofer et al., 2004; Voruganti et al., 
2002); remarkably and unexpectedly, a significant relation with the physical domain of QoL 
is lacking which may reflect the composition of this domain with items of pain, energy, 
sleep, mobility, activities, medication and work; these are not likely to be related to EPS. 
Sexual Anhedonia predicted a lower score on the social relationship QoL-domain and 
Diminished Sociability a lower score in the environmental QoL-domain which is in 
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accordance with our expectations. Interestingly, Affective Flattening, EPS, Sexual Anhedonia 
and probably also Sedation, are all at least partially mediated through dopaminergic 
mechanisms in the brain, which is known to be related to the experience of well-being and 
QoL (Voruganti et al., 2002; De Haan et al., 2003). Weight Gain and Increased Sleep after 
being controlled for the other subscales and background variables appeared not to be 
related to quality of life. Although undesired according to most people, these are probably 
not mediated by dopaminergic mechanisms and therefore falling short of a significant 
relationship with quality of life (Voruganti et al., 2002; De Haan et al., 2003). Moreover, 
increased sleep could be an ambivalent domain in relation to Qol because it may reflect the 
experience of a desired as well as an undesired effect (Wolters et al., 2003). 
This study shows multiple desired as well as undesired effects of antipsychotic medication in 
relation to quality of life: desired predicting an increase and undesired predicting a decrease 
in Qol. For patients, this may reflect a trade-off between these two kinds of effects, possibly 
influencing their decision to (dis)continue the antipsychotic medication. Assessing this 
balance of treatment effects from a patients’ perspective with the SRA and discussing them 
with their clinician may be helpful in guiding the choice and dosing of medication, and 
consequently in reducing drop-out and relapse and possibly increasing QoL. Future studies 
should focus on evaluating the SRA in the prediction of treatment adherence and relapse 
and using the SRA in intervention studies aimed to optimize treatment quality and quality of 
life. 
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